Affiliation: University of Athens
- Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretionAntonis Kattamis
Haematologica 88:1423-5. 2003
- The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia majorAntonis Kattamis
First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Athens 11527, Greece
Haematologica 91:809-12. 2006..We conclude that hepcidin expression is regulated mainly by increased erythropoietic activity rather than by iron load and that hepcidin plays a central regulatory role in iron circulation and iron toxicity in patients with thalassemia...
- Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyureaAntonis Kattamis
First Department of Pediatrics, University of Athens School of Medicine, Athens, Greece
Pediatr Hematol Oncol 21:335-42. 2004..HU seems to be effective in a high proportion of young patients with sickle cell disease and in particular with S/beta(thal), but cannot eliminate occurrence of serious adverse events...
- Combined therapy with deferoxamine and deferiproneAntonis Kattamis
First Department of Pediatrics, University of Athens, Medical School, Aghia Sophia Children s Hospital, Thivon and Levadias, Goudi 115 27, Greece
Ann N Y Acad Sci 1054:175-82. 2005..Combining the available iron chelators offers many therapeutic options that can be tailored to each patient individually. It is an exciting advance in treating hemosiderosis in thalassemic patients...
- Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trialAntonis Kattamis
First Department of Pediatrics, University of Athens, Medical School, Aghia Sophia Children s Hospital, Thivon and Levadias, Goudi 11527, Greece
Blood Cells Mol Dis 36:21-5. 2006..Prolonged use of combined therapy with DFP and DFO is effective in decreasing iron load and improving cardiac function. Its possible association with higher incidence of agranulocytosis emphasizes the need for close monitoring...
- Impact of magnetic resonance imaging on cardiac mortality in thalassemia majorGiorgos Chouliaras
Thalassaemia Unit, 1st Dept of Paediatrics, University of Athens, Aghia Sophia Children s Hospital, Athens, Greece
J Magn Reson Imaging 34:56-9. 2011..To evaluate whether the introduction of magnetic resonance imaging (MRI) in the management of thalassemia major (TM) patients has affected the risk of cardiac death...
- Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta-thalassaemiaIno Kanavaki
Department of Clinical Biochemistry, Aghia Sophia Children s Hospital, Athens, Greece
Eur J Clin Invest 42:27-33. 2012..Chronic inflammation also plays an important role in the pathophysiology of SCD. We aimed to investigate endothelial activation in Caucasian Greek patients with SCD by means of measuring adhesion molecules and markers of inflammation...
- Cystatin C levels in patients with beta-thalassemia during deferasirox treatmentIoannis Papassotiriou
Department of Clinical Biochemistry, Aghia Sophia Children s Hospital, Athens, Greece
Blood Cells Mol Dis 44:152-5. 2010..However hemodynamic signals such as LVEF alterations and iron mobilization do appear to affect changes in cystatin C concentration...
- Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fractionGiorgos L Chouliaras
Thalassaemia Unit, First Department of Paediatrics, University of Athens, Aghia Sophia Children s Hospital, Athens, Greece
Br J Haematol 151:397-401. 2010..Patients with cardiac T2*≤8 ms require careful and intensive management. This risk decreases with increasing values of T2* but even in mildly loaded patients the probability of impaired LVEF is not negligible...
- R2 relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patientsEfthymia Alexopoulou
Second Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece
J Magn Reson Imaging 23:163-70. 2006..To evaluate the usefulness of a time-efficient MRI method for the quantitative determination of tissue iron in the liver and heart of beta-thalassemic patients using spin-spin relaxation rate, R2, measurements...
- Hb Souli, a 6 bp in-frame deletion on the HBA2 gene (HBA2: c.[41-46delCCTGGG]) leads to α-thalassemia intermedia, when in trans to a single α-globin gene deletionAntonis Kattamis
First Department of Pediatrics, Athens University Medical School, Athens, Greece
Hemoglobin 39:55-7. 2015..41-46delCCTGGG]) is, to the best of our knowledge, the first variant to be reported where both amino acid residues, α13Ala and α14Trp, are deleted, leading to unstable and rapidly degraded α-globin chains...
- A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected birthsErsi Voskaridou
Thalassaemia Center, Laikon General Hospital, 16 Sevastoupoleos Street, GR 11526, Athens, Greece
Ann Hematol 91:1451-8. 2012....
- Evaluation of Intracranial Cerebral Blood Flow Velocities in Splenectomised and Non-Splenectomised Patients with β-Thalassemia Intermedia Using Transcranial Doppler SonographyAikaterini Kanavaki
First Department of Pediatrics, University of Athens, Medical School, Athens, Greece
In Vivo 29:501-4. 2015..These could be due to cerebral large-vessel disease. Based on the example of sickle cell disease, we applied transcranial Doppler sonography (TCD) to evaluate cerebral vessels velocity as a possible indicator of cerebral vasculopathy...
- Clinical phenotype and genetic analysis of RPS19, RPL5, and RPL11 genes in Greek patients with Diamond Blackfan AnemiaPolyxeni Delaporta
First Department of Pediatrics, University of Athens, Greece
Pediatr Blood Cancer 61:2249-55. 2014..Here, we present our findings from the study of 17 patients recorded in the Greek DBA registry...
- Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general populationVassilis Ladis
Thalassaemia Unit, 1st Department of Paediatrics, University of Athens, Aghia Sophia Children s Hospital, Athens, Greece
Eur J Haematol 86:332-8. 2011..With transfusions and chelation therapy, the prognosis for transfusion-dependent beta thalassaemia has changed from being fatal in early childhood to a chronic disorder with prolonged survival...
- Soluble endothelial adhesion molecules and inflammation markers in patients with beta-thalassemia intermediaIno Kanavaki
Department of Clinical Biochemistry, Aghia Sophia Children s Hospital, 115 27 Athens, Greece
Blood Cells Mol Dis 43:230-4. 2009..Furthermore, these findings are of particular importance in patients who can otherwise be characterized by a subtle clinical phenotype and may have an important role in their clinical care...
- Successful management of a small infant with Kasabach-Merritt phenomenon using vincristine: a case reportMarina Economou
a1st Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital bNeonatal Care Unit, Hippokration General Hospital, Thessaloniki c1st Pediatric Department of University of Athens, Agia Sophia Hospital, Athens, Greece
Blood Coagul Fibrinolysis 25:777-9. 2014....
- A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemiaRenzo Galanello
Department of Biomedical Science and Biotechnology, University of Cagliari, Ospedale Microcitemico, Italy
Haematologica 91:1241-3. 2006..There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen...
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaMaria Domenica Cappellini
Fondazione Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena IRCCS, Universita di Milano, Via F Sforza 35, 20122 Milan, Italy
Blood 107:3455-62. 2006..No agranulocytosis, arthropathy, or growth failure was associated with deferasirox administration. Deferasirox is a promising once-daily oral therapy for the treatment of transfusional iron overload...
- Treatment of thalassemia with hydroxyurea: an indispensable alternative therapyAntonis Kattamis
J Pediatr Hematol Oncol 29:729-30. 2007
- Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and IranAli Taher
Internal Medicine, American University of Beirut, Beirut, Lebanon
Thromb Haemost 96:488-91. 2006..Due to the increased risk of thromboembolic events, the rationale for splenectomy should perhaps be re-assessed and the role of transfusion therapy for the prophylaxis of thrombosis, among other complications, be evaluated prospectively...
- Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up studyVassiliki Syriopoulou
Haematologica 90:129-31. 2005..Interferon induced sustained virologic and biochemical response in 45% of participants and histologic improvement in 50% of patients who had paired liver biopsies. Splenectomy was the only independent predictor of an unfavorable outcome...